title: Short-term effects of the smoke-free legislation on haemostasis and systemic inflammation due to second hand smoke exposure. The AERER study.
abstract: It was the objective of this study to assess the effect of the implementation of the smoke-free legislation on haemostasis and systemic inflammation in second-hand smoking (SHS)-exposed healthy volunteers. Fibrin-rich clot properties, platelet reactivity and inflammatory biomarkers were measured before and four months following the implementation of the smoke-free legislation in gender and age-matched healthy volunteers exposed (n=23, exposed) and unexposed (n=23, controls) to occupational SHS. The primary objective was to compare fibrin-rich clot stiffness before and after implementation of the smoke-free legislation. There was 40% reduction in fibrin-rich clot stiffness following the implementation of the smoke-free legislation in SHS-exposed volunteers (17 ± 7 vs. 10.6 ± 7 dynes/cm², before and after, respectively, p=0.001). These dramatic changes were associated with a 20% reduction in fibrin fiber density (p<0.01) and a 20% reduction in clot lysis time (p=0.05). No change in fibrin properties was observed in the control group of SHS-unexposed volunteers related to the implementation of the smoke-free legislation. Of interest, neither platelet reactivity nor systemic inflammatory biomarkers were changed in either group. The smoke-free legislation is associated with significant changes in fibrin-rich clot properties toward a less thrombogenic conformation with a better fibrinolysis response while neither platelet reactivity nor systemic inflammatory biomarkers are modified. These improvements may explain the observed reduction in acute coronary syndrome following the implementation of the smoke-free legislation.
authors.affiliation: Institut de Cardiologie, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Cayla
authors.forename: P
authors.initials: P
authors.lastname: Sié
authors.forename: J
authors.initials: J
authors.lastname: Silvain
authors.forename: D
authors.initials: D
authors.lastname: Brugier
authors.forename: J-P
authors.initials: JP
authors.lastname: Cambou
authors.forename: D
authors.initials: D
authors.lastname: Thomas
authors.forename: A
authors.initials: A
authors.lastname: Pena
authors.forename: S A
authors.initials: SA
authors.lastname: O'Connor
authors.forename: A
authors.initials: A
authors.lastname: Bura
authors.forename: J-B
authors.initials: JB
authors.lastname: Ruidavets
authors.forename: G
authors.initials: G
authors.lastname: Montalescot
authors.forename: J-P
authors.initials: JP
authors.lastname: Collet
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology; D015415:Biomarkers / Q000097:blood; D003018:Clot Retraction; D005342:Fibrinolysis; D005602:France; D006487:Hemostasis; D006801:Humans; D015994:Incidence; D007249:Inflammation; D007878:Legislation as Topic / Q000706:statistics & numerical data*; D016273:Occupational Exposure / Q000009:adverse effects / Q000331:legislation & jurisprudence; D015539:Platelet Activation; D014028:Tobacco Smoke Pollution / Q000009:adverse effects / Q000331:legislation & jurisprudence*
chemical_list: D015415:Biomarkers; D014028:Tobacco Smoke Pollution